Expanding Options in the Treatment of Prostate Cancer: The Impact of Prognostic Biomarkers on Patient Outcomes

This activity is an archive from the live session from the 2019 Fall Managed Care Forum.

This activity is valid from January 1, 2020

CME credits not offered on this activity

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Sponsored by Myriad Genetics

Description:
Prostate cancer is the most commonly diagnosed non-cutaneous cancer in men in the United States (US) and remains the second leading cause of cancer deaths among American men, with an estimated 164,690 new cases diagnosed per year. After evaluating data on the annual spend, treatment decisions and outcomes of prostate cancer, healthcare professionals have determined there are several problems with the traditional diagnostic and clinical pathway. Traditionally, prostate cancer risk has been measured by PSA, Gleason score and stage, while diagnosis and treatment protocols have barely changed. This traditional evaluation doesn’t provide all of the necessary information to appropriately identify prostate cancer risk and accurately determine feasible treatment options. In addition, the most recent guidelines on prostate cancer, published by the National Comprehensive Cancer Network (NCC), state the necessary consideration of utilizing gene expression assays in men with low or favorable intermediate disease. Although clinical parameters such as the Gleason score remains the mainstay measurement for prostate cancer severity it does not measure cell proliferation, a critical trait of cancer. This presentation explores novel methods to the prostate cancer treatment paradigm by incorporating a collaborative care approach. This technique includes utilizing prognostic testing with updated gene assays to develop a more accurate diagnosis. Once diagnosis is established the appropriate treatment options can be determined while lowering the cost of care, and ultimately improving outcomes and patient quality of life.
 

Faculty: Henry Garlich
Director
Healthcare Value Solutions & Enhanced Clinical Programs
Blue Shield of California

The National Association of Managed Care Physicians (NAMCP) and/or the presenter has copyright or has received permissions for use of materials
provided in this activity.

Sponsored by Myriad Genetics

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

PLEASE CLICK HERE TO VIEW THE PRESENTATION